| Identification | Back Directory | [Name]
CC401 HCl | [CAS]
1438391-30-0 | [Synonyms]
CC-401 (hydrochloride)
CC-401 dihydrochloride >=95% (HPLC)
CC 401 HYDROCHLORIDE; CC401 HYDROCHLORIDE; CC401 HCL
3-[3-[2-(1-Piperidinyl)ethoxy]phenyl]-5-(1H-1,2,4-triazol-5-yl)-1H-indazole hydrochloride (1:1) | [Molecular Formula]
C22H25ClN6O | [MDL Number]
MFCD21364765 | [MOL File]
1438391-30-0.mol | [Molecular Weight]
424.927 |
| Chemical Properties | Back Directory | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 100 mg/mL (235.33 mM; Need ultrasonic) | [form ]
White powder. | [color ]
White to off-white | [Water Solubility ]
H2O: 10mg/mL, clear | [InChI]
1S/C22H24N6O.ClH/c1-2-9-28(10-3-1)11-12-29-18-6-4-5-16(13-18)21-19-14-17(22-23-15-24-27-22)7-8-20(19)25-26-21;/h4-8,13-15H,1-3,9-12H2,(H,25,26)(H,23,24,27);1H | [InChIKey]
OIBVXKYKWOUGAO-UHFFFAOYSA-N | [SMILES]
[H]Cl.C1(C2=NC=NN2)=CC3=C(NN=C3C4=CC=CC(OCCN5CCCCC5)=C4)C=C1 |
| Hazard Information | Back Directory | [Uses]
CC-401 inhibits c-JUN N-terminal kinases (JNKs) by binding to its ATP-binding site. JNKs belong to the MAP kinase family and respond to stress signals such as heat, cytokines, and osmotic shock. | [Biological Activity]
CC-401 is a cell penetrantpotent and selective c-Jun N terminal kinase (JNK) inhibitor th at blocks JNK signaling in the r at obstructed kidney and inhibits renal fibrosis in the unilateral ureteral obstruction model. CC-401 in combination with chemotherapy exhibits synergism in colon cancer cell lines. | [in vivo]
The staining of p-JNK is moderately induced in bevazicumab and Oxaliplatin treatments as compared to control, and in the CC-401-treated samples p-cJun content is significantly lower, consistent with effective JNK inhibition. DNA damage is modestly elevated in combined treatments with CC-401[2]. CC-401 treatment from days 7 to 24 slows the progression of proteinuria, which is significantly reduced compared to the no-treatment and vehicle groups at days 14 and 21. However, there is still an increase in the degree of proteinuria at day 21 in CC-401-treated rats compared to proteinuria at day 5. The vehicle and no-treatment groups developed renal impairment at day 24 as shown by an increase in serum creatinine. This is prevented by CC-401 treatment[3]. | [IC 50]
JNK: 25-50 nM (Ki) |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
| Company Name: |
SPIRO PHARMA
|
| Tel: |
|
| Website: |
www.spiropharma.com.cn |
|